SMMT
Summit Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.80
+6.76%Price chart
Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3
Key dataNov 3, 2026
Open$14.92
From 52W high−40.11%
Volume6.01M
Market cap$12.64B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 3, 2026
Open
$14.92
From 52W high
−40.11%
Volume
6.01M
Market cap
$12.64B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−14.0x
P/E (TTM)
—
RSI (14)
51.1
MomentumView details →
1D Return
+6.76%
YTD Return
−8.23%
SummaryUpdated Jun 1, 2026
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company founded in 2003 and headquartered in Cambridge, Massachusetts. Originally focused on developing treatments for infectious diseases, the company underwent a strategic transformation in 2022 when it pivoted entirely to oncology. Summit acquired the rights to develop and commercialize ivonescimab, a promising cancer immunotherapy, through a landmark $500 million licensing agreement with Chinese biotech company Akeso. The company is now focused exclusively on advancing this bispecific antibody through late-stage clinical trials for various cancer indications, particularly non-small cell lung cancer.
Similar companies
Latest newsMore news →
Summit Therapeutics Inc. and Lunit, Inc. announced a research agreement to evaluate Lunit SCOPE IO for tumor microenvironment analysis supporting Summit’s immuno-oncology development programs with ivonescimab.11d agoSummit Therapeutics Inc. launched a Phase II/III study of ivonescimab for biliary tract cancer, comparing its survival benefits with established immunotherapy regimens.12d agoSummit Therapeutics announced a clinical trial collaboration with ECOG-ACRIN Cancer Research Group to evaluate ivonescimab with chemotherapy against pembrolizumab or durvalumab in a Phase II/III biliary tract cancer study.14d ago